Baillie Gifford's position in Alnylam Pharmaceuticals is currently worth $945 Million. That's 0.78% of their equity portfolio (29th largest holding). The investor owns 2.80% of the outstanding Alnylam Pharmaceuticals stock. The first Alnylam Pharmaceuticals trade was made in Q1 2013. Since then Baillie Gifford bought shares 25 more times and sold shares on 22 occasions. The stake costed the investor $343 Million, netting the investor a gain of 176% so far.